IceCure Medical - רווח נקי למניה בארבעת הרבעונים האחרונים ICCM

This price chart for IceCure Medical Ltd (ICCM) reflects EPS dynamics, which currently stand at 20.90. Growth is driven by proprietary tumor freezing methods and a complex certification process. The business relies on the sale of ProSense disposable probes and the support of insurance reimbursements in the US. High physician loyalty and a unique cooling mechanism provide the company with significant pricing power.
IceCure Medical, Ltd. - פילוחים אנליטיים ומדדי מפתח (ICCM)

To isolate fundamental stability from market noise, an investor must analyze the trailing twelve months (TTM) net income per share, which measures the real growth rate of return on equity. By analyzing the annual growth trend of TTM net income per share, one can confirm the effectiveness of the IceCure Medical Ltd (ICCM) model, where a hybrid approach to cryoballoon production minimizes vendor risks and stabilizes financial results.